Kwon Y, Kim ES, Choe YH, Kim MJ. How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study. World J Gastroenterol 2022; 28(28): 3666-3681 [PMID: 36161040 DOI: 10.3748/wjg.v28.i28.3666]
Corresponding Author of This Article
Mi Jin Kim, MD, PhD, Associate Professor, Department of Pediatrics, Samsung Medical Center, Ilwon-ro 81, Gangnam-gu, Seoul 06351, South Korea.email@example.com
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
aP value and 95%CI for hazard ratio were corrected by Bonferroni's method due to multiple testing.
bCox’s proportional hazard regression using counting process.
cThe robust sandwich covariance estimate was used to account for the within-subject correlation.
dPediatric Ulcerative Colitis Activity Index (PUCAI) is a 6-item disease activity index intended for use in pediatric UC clinical trials with a score ranging from 0-85.
CI: Confidence interval; HR: Hazard ratio.
Citation: Kwon Y, Kim ES, Choe YH, Kim MJ. How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study. World J Gastroenterol 2022; 28(28): 3666-3681